RENX Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.08 |
| 52 Week High | UK£0.33 |
| 52 Week Low | UK£0.065 |
| Beta | 1.94 |
| 1 Month Change | -11.11% |
| 3 Month Change | -33.33% |
| 1 Year Change | -75.38% |
| 3 Year Change | -96.36% |
| 5 Year Change | -96.58% |
| Change since IPO | -93.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| RENX | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | -5.9% | -0.9% | -1.0% |
| 1Y | -75.4% | -33.3% | -3.0% |
Return vs Industry: RENX underperformed the UK Healthcare Services industry which returned -33.3% over the past year.
Return vs Market: RENX underperformed the UK Market which returned -3% over the past year.
Price Volatility
| RENX volatility | |
|---|---|
| RENX Average Weekly Movement | 6.2% |
| Healthcare Services Industry Average Movement | 6.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: RENX has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: RENX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| RENX fundamental statistics | |
|---|---|
| Market cap | UK£26.50m |
| Earnings (TTM) | -UK£21.53m |
| Revenue (TTM) | UK£2.21m |
12.0x
P/S Ratio-1.2x
P/E RatioIs RENX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENX income statement (TTM) | |
|---|---|
| Revenue | US$2.89m |
| Cost of Revenue | US$2.33m |
| Gross Profit | US$568.00k |
| Other Expenses | US$28.72m |
| Earnings | -US$28.15m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 19.63% |
| Net Profit Margin | -972.87% |
| Debt/Equity Ratio | -599.3% |
How did RENX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 21:10 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Renalytix Plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Mark Massaro | BTIG |
| David Westenberg | Guggenheim Securities, LLC |